Literature DB >> 8890772

The apolipoprotein E allele epsilon 4 does not correlate with the number of senile plaques or neurofibrillary tangles in patients with Alzheimer's disease.

M Landén1, A Thorsell, A Wallin, K Blennow.   

Abstract

BACKGROUND AND OBJECTIVES: Apolipoprotein E (apoE) has been implicated in regenerative processes in the brain after trauma, as well as in the pathogenesis of Alzheimer's disease. Inheritance of a specific apo epsilon allele (apo epsilon 4) determines in part the risk and the mean age at onset of Alzheimer's disease. ApoE has been found to bind isoform specifically to beta-amyloid protein, the major component of senile plaques, and to the microtubule associated protein tau, which forms paired helical filaments and neurofibrillary tangles. The aim was to further examine the relation between apo epsilon alleles, especially apo epsilon 4, and the development of neuropathological changes associated with Alzheimer's disease.
METHODS: Brains of patients with Alzheimer's disease (n = 44) and vascular dementia (n = 11) and of age matched controls (n = 29) were studied. Senile plaques and neurofibrillary tangles in the hippocampus and frontal cortex were quantified.
RESULTS: No correlation was found between the number of apo epsilon 4 alleles and the number of senile plaques and neurofibrillary tangles in the hippocampus or the frontal cortex of patients with Alzheimer's disease, or vascular dementia, or control groups. No significant differences in duration or severity of dementia were found between patients with or. without the apo epsilon 4 allele. No increased frequency of apo epsilon 4 was found in vascular dementia. CONCLUSION AND COMMENT: Although the apo epsilon genotype clearly affects whether Alzheimer's disease will develop or not, the present study suggests that it has no influence on pathology or clinical intellectual status, once the dementia has manifested itself. No increased apo epsilon 4 allele frequency was found in neuropathologically diagnosed patients with vascular dementia in whom concomitant Alzheimer's disease can be excluded.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8890772      PMCID: PMC486574          DOI: 10.1136/jnnp.61.4.352

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  47 in total

1.  Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage.

Authors:  M A Pericak-Vance; J L Bebout; P C Gaskell; L H Yamaoka; W Y Hung; M J Alberts; A P Walker; R J Bartlett; C A Haynes; K A Welsh
Journal:  Am J Hum Genet       Date:  1991-06       Impact factor: 11.025

2.  Cloning of hippocampal poly(A) RNA sequences that increase after entorhinal cortex lesion in adult rat.

Authors:  J Poirier; M Hess; P C May; C E Finch
Journal:  Brain Res Mol Brain Res       Date:  1991-02

3.  Plasma apolipoproteins in patients with multi-infarct dementia.

Authors:  H Shimano; S Ishibashi; T Murase; T Gotohda; N Yamada; F Takaku; E Ohtomo
Journal:  Atherosclerosis       Date:  1989-10       Impact factor: 5.162

4.  Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning.

Authors:  J Poirier; M Hess; P C May; C E Finch
Journal:  Brain Res Mol Brain Res       Date:  1991-09

5.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.

Authors:  E H Corder; A M Saunders; W J Strittmatter; D E Schmechel; P C Gaskell; G W Small; A D Roses; J L Haines; M A Pericak-Vance
Journal:  Science       Date:  1993-08-13       Impact factor: 47.728

6.  Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid.

Authors:  T Wisniewski; B Frangione
Journal:  Neurosci Lett       Date:  1992-02-03       Impact factor: 3.046

7.  Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease.

Authors:  Y Namba; M Tomonaga; H Kawasaki; E Otomo; K Ikeda
Journal:  Brain Res       Date:  1991-02-08       Impact factor: 3.252

Review 8.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology.

Authors:  R W Mahley
Journal:  Science       Date:  1988-04-29       Impact factor: 47.728

9.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Authors:  W J Strittmatter; A M Saunders; D Schmechel; M Pericak-Vance; J Enghild; G S Salvesen; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

10.  Oligodendrocytes but not astrocytes express apolipoprotein E after injury of rat optic nerve.

Authors:  G Stoll; H W Meuller; B D Trapp; J W Griffin
Journal:  Glia       Date:  1989       Impact factor: 7.452

View more
  14 in total

1.  APOE ε4 influences β-amyloid deposition in primary progressive aphasia and speech apraxia.

Authors:  Keith A Josephs; Joseph R Duffy; Edythe A Strand; Mary M Machulda; Matthew L Senjem; Val J Lowe; Clifford R Jack; Jennifer L Whitwell
Journal:  Alzheimers Dement       Date:  2014-06-28       Impact factor: 21.566

Review 2.  Apolipoprotein E as a Therapeutic Target in Alzheimer's Disease: A Review of Basic Research and Clinical Evidence.

Authors:  Yu Yamazaki; Meghan M Painter; Guojun Bu; Takahisa Kanekiyo
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

3.  Apolipoprotein E allelotype is associated with neuropathological findings in Alzheimer's disease.

Authors:  Neena Theresa Kumar; Knut Liestøl; Else Marit Løberg; Henrik Mikael Reims; Jan Mæhlen
Journal:  Virchows Arch       Date:  2015-04-22       Impact factor: 4.064

4.  A population study of apoE genotype at the age of 85: relation to dementia, cerebrovascular disease, and mortality.

Authors:  I Skoog; C Hesse; O Aevarsson; S Landahl; J Wahlström; P Fredman; K Blennow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-01       Impact factor: 10.154

5.  Associations Between Sub-Threshold Amyloid-β Deposition, Cortical Volume, and Cognitive Function Modulated by APOE ɛ4 Carrier Status in Cognitively Normal Older Adults.

Authors:  Dong Woo Kang; Sheng-Min Wang; Yoo Hyun Um; Nak Young Kim; Chang Uk Lee; Hyun Kook Lim
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

6.  Amyloid mediates the association of apolipoprotein E e4 allele to cognitive function in older people.

Authors:  D A Bennett; J A Schneider; R S Wilson; J L Bienias; E Berry-Kravis; S E Arnold
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09       Impact factor: 10.154

7.  Decreases in plasma A beta 1-40 levels with aging in non-demented elderly with ApoE-epsilon 4 allele.

Authors:  N Pomara; B Shao; T Wisniewski; P D Mehta
Journal:  Neurochem Res       Date:  1998-12       Impact factor: 3.996

8.  Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients.

Authors:  Manja Lehmann; Pia M Ghosh; Cindee Madison; Anna Karydas; Giovanni Coppola; James P O'Neil; Yadong Huang; Bruce L Miller; William J Jagust; Gil D Rabinovici
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-08-21       Impact factor: 10.154

9.  The effect of APOE-epsilon4 on dementia is mediated by Alzheimer neuropathology.

Authors:  James A Mortimer; David A Snowdon; William R Markesbery
Journal:  Alzheimer Dis Assoc Disord       Date:  2009 Apr-Jun       Impact factor: 2.703

Review 10.  The role of apolipoprotein E in Alzheimer's disease.

Authors:  Jungsu Kim; Jacob M Basak; David M Holtzman
Journal:  Neuron       Date:  2009-08-13       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.